Urogen Pharma (NASDAQ:URGN) Insider Sells $37,383.32 in Stock

Key Points

• Insider Mark Schoenberg sold 871 Urogen Pharma shares for $37,383 at an average price of $42.92, reducing his holdings by 1.43% to 59,882 shares. He has also sold substantially larger blocks of shares in recent months.
• Urogen shares rose 1.8% to $44.60, with a market capitalization of approximately $2.18 billion. The company’s latest quarterly revenue of $72.46 million exceeded expectations, although its adjusted loss per share missed analyst estimates.
• Analyst sentiment remains generally positive, with a consensus rating of “Moderate Buy” and an average price target of $50.38; institutional investors own approximately 91.29% of the stock.

Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 871 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total value of $37,383.32. Following the sale, the insider owned 59,882 shares of the company's stock, valued at $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Mark Schoenberg also recently made the following trade(s):

• On Thursday, August 20th, Mark Schoenberg sold 60,677 shares of Urogen Pharma stock. The stock was sold at an average price of $47.05, for a total value of $2,854,852.85.
• On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $40.00, for a total value of $400,000.00.
• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $35.01, for a total value of $350,100.00.

Urogen Pharma Stock Up 1.8%

Shares of Urogen Pharma stock traded up $0.79 on Wednesday, hitting $44.60. The stock had a trading volume of 648,104 shares, compared to its average volume of 807,203. Urogen Pharma has a one year low of $15.86 and a one year high of $50.81. The stock's 50-day simple moving average is $43.02 and its two-hundred day simple moving average is $31.15. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -22.61 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. As a group, equities analysts predict that Urogen Pharma will post -0.2 EPS for the current fiscal year.

Institutional Trading of Urogen Pharma

Several institutional investors and hedge funds have recently bought and sold shares of URGN. Paradigm Biocapital Advisors LP boosted its position in Urogen Pharma by 6.1% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company's stock valued at $104,773,000 after acquiring an additional 257,564 shares in the last quarter. BlackRock Inc. bought a new position in shares of Urogen Pharma in the 2nd quarter worth approximately $117,814,000. Morgan Stanley lifted its stake in shares of Urogen Pharma by 1.4% in the 4th quarter. Morgan Stanley now owns 2,562,901 shares of the company's stock valued at $60,023,000 after purchasing an additional 34,455 shares during the period. Jefferies Financial Group Inc. purchased a new position in shares of Urogen Pharma in the 2nd quarter valued at approximately $80,947,000. Finally, Soleus Capital Management L.P. bought a new stake in shares of Urogen Pharma during the second quarter valued at approximately $29,934,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on URGN shares. Weiss Ratings restated a "sell (d-)" rating on shares of Urogen Pharma in a report on Friday, July 17th. TD Cowen lifted their price objective on Urogen Pharma from $50.00 to $60.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Guggenheim boosted their target price on Urogen Pharma from $42.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. HC Wainwright upped their target price on Urogen Pharma from $45.00 to $75.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Finally, Oppenheimer raised their price target on Urogen Pharma from $40.00 to $50.00 and gave the stock an "outperform" rating in a research note on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Urogen Pharma currently has an average rating of "Moderate Buy" and a consensus price target of $50.38.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.